Gold prices steady ahead of Fed decision, Trump’s tariff deadline
David F. Novack, President and Chief Operating Officer of Dynavax Technologies Corp. (NASDAQ:DVAX), a biotechnology company with a market capitalization of $1.69 billion and "GREAT" financial health according to InvestingPro, has sold a significant portion of his holdings in the company. According to a recent SEC filing, Novack sold 14,020 shares of common stock on March 18, 2025, at an average price of $13.58 per share, totaling $190,391. This transaction was executed under a pre-established 10b5-1 trading plan, which was adopted on December 6, 2024. Following the sale, Novack retains ownership of 8,078 shares in the company. The sale was conducted in multiple trades with prices ranging between $13.47 and $13.66, with the stock currently trading near its 52-week high of $14.63. Notably, while this insider sale has occurred, InvestingPro data reveals that management has been actively buying back shares, with 12 additional exclusive insights available for subscribers.
In other recent news, Dynavax Technologies reported its fourth-quarter 2024 earnings with an EPS of $0.05, surpassing the forecast of $0.04, but missed its revenue forecast, reporting $71.1 million against an expected $72.44 million. Despite the revenue miss, analysts at H.C. Wainwright maintained a Buy rating with a $31 price target, while JMP Securities raised the price target to $33, maintaining a Market Perform rating. Dynavax’s HEPLISAV-B sales reached record levels with a 39% year-over-year increase, contributing to full-year net sales of $268 million, marking a 26% increase from the previous year. The company continues its $200 million share repurchase program, having completed $100 million so far, with plans to acquire the remaining $100 million by the end of 2025.
In another development, Recursion has strengthened its Board of Directors with the appointments of Namandjé Bumpus, Ph.D., and Elaine Sun, aiming to enhance its strategic leadership. Dr. Bumpus brings experience from her role as the FDA’s Principal Deputy Commissioner, while Sun adds extensive life sciences and financial expertise. These appointments are expected to bolster Recursion’s growth and clinical pipeline development. Both companies are making strategic moves to enhance their operations and shareholder value, with Dynavax focusing on expanding its market share and product pipeline, while Recursion aims to leverage its Recursion OS platform for drug discovery advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.